Galapagos : The end of the year was marked by the exit of Jyseleca, the discontinuation of its CD19 CAR-T in rSLE
>Cost control already in place - Galapagos reported its full-year 2023 results after the US market closed. After the effective sale of Jyseleca to Alfasigma last January, the publication is not so clear-cut between consolidated activities and discontinued operations. Group revenues came to € 783.5m, compared with € 545m, including € 112m from Jyseleca. The Jyseleca business made a positive contribution to net profit, with net profit from the now discontinued operation...Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.